BostonSight PROSE Treatment – Impact at Five Years

Josh AgranatJoshua S. Agranat (pictured), a Boston University School of Medicine student (graduating in May 2016), frequent BostonSight collaborator, and future ophthalmologist, served as first author on a recent publication in the British Journal of Ophthalmology entitled Prosthetic Replacement of the Ocular Surface Ecosystem: Impact at 5 Years. The publication is based on a retrospective review, of clinical, manufacturing, and quality databases at BostonSight®, which sought to examine the long-term effectiveness of BostonSight PROSE treatment.

The initial treatment data and five year follow-up data for 121 patients, who were seen at BostonSight, Needham, MA, in consultation for PROSE treatment from January – June 2008, was reviewed to determine the impact of PROSE treatment five years post-treatment. Of those 121 patients, 57 had a primary indication of distorted corneal surface; while 64 patients were treated for ocular surface disease.

Patients included in the study completed the Visual Functioning Questionnaire (VFQ-25) prior to PROSE treatment, 6 months after completing PROSE treatment, and then again 5 years post-treatment. For the patients still using their PROSE devices, VFQ-25 scores rose an average of 23 points at the six-month mark; this figure did not decline significantly at the five year mark.

We are happy to report that almost 74% of patients included in the study are still wearing their PROSE devices five years post-treatment. Of those patients who were no longer using their PROSE devices, only three reported an ophthalmic complication (such as redness or opacification) as the reason for discontinuation of wear.

Thanks to Josh, and co-authors Nicole R. Kitos (also of Boston University School of Medicine) and BostonSight Medical Director Deborah S. Jacobs, MD, for completing this important study, which concluded that “PROSE treatment offers continued benefit, as defined by improved visual function and continued device wear at five years, in patients with complex corneal disease.”